Abstract
The neurohumoral regulation of growth hormone secretion is mediated in part by two hypothalamic peptides that reach the anterior pituitary via the hypothalamo-hypophysial portal blood system1. Somatostatin inhibits the release of growth hormone2, whereas growth hormone-releasing factor (GRF) positively regulates both growth hormone synthesis3,4 and secretion5,6. Two forms of human GRF, 40 and 44 amino acids long, have been characterized from extra-hypothalamic tumours7,8 as well as from the hypothalamus9. Analysis of human GRF complementary DNA10,11 and genomic12 clones indicates that the GRF peptides are first synthesized as a 107- or 108-amino-acid precursor protein. To examine the physiological consequences of GRF expression, we have established strains of transgenic mice containing a fusion gene including the promoter/regulatory region of the mouse metal-lothionein-I (MT-I) gene13 and the coding region of the human GRF gene12. We report that expression of the human GRF precursor protein in these animals results in measurable levels of human GRF and increased levels of mouse growth hormone in plasma and accelerated growth rates relative to control littermates. These results demonstrate a direct role for GRF in the positive regulation of somatic growth. Unexpectedly, female transgenic mice carrying the MT-GRF fusion gene are fertile, in contrast to female transgenic mice expressing human or rat growth hormone, which are generally infertile. These transgenic mouse strains should provide useful animal models for the study of several types of human growth disorders.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Martin, J. B. Physiologist 22, 23–29 (1979).
Brazeau, P. et al. Science 179, 77–79 (1973).
Baringa, M. et al. Nature 306, 84–85 (1983).
Gick, G. et al. Proc. natn. Acad. Sci. U.S.A. 81, 1553–1555 (1984).
Brazeau, P. et al. Proc. natn. Acad. Sci. U.S.A. 79, 7909–7913 (1982).
Vale, W., Vaughan, J., Yamamoto, G., Spiess, J. & Rivier, J. Endocrinology 112, 1553–1555 (1983).
Rivier, J., Spiess, J., Thorner, M. & Vale, W. Nature 300, 276–278 (1982).
Guillemin, R. et al. Science 218, 585–587 (1982).
Ling, N. et al. Proc. natn. Acad. Sci. U.S.A. 81, 4302–4306 (1984).
Mayo, K. E., Vale, K. E., Rivier, J., Rosenfeld, M. G. & Evans, R. M. Nature 306, 86–88 (1983).
Gubler, U. et al. Proc. natn. Acad. Sci. U.S.A. 80, 4311–4314 (1983).
Mayo, K. E. et al. Proc. natn. Acad. Sci. U.S.A. 82, 63–67 (1985).
Durnam, D. M., Perrin, F., Gannon, F. & Palmiter, R. D. Proc. natn. Acad. Sci. U.S.A. 77, 6511–6515 (1980).
Palmiter, R. D. et al. Nature 300, 611–615 (1982).
Palmiter, R. D., Norstedt, G., Gelinas, R. E., Hammer, R. E. & Brinster, R. L. Science 222, 809–814 (1983).
Hammer, R. E., Palmiter, R. D. & Brinster, R. L. Nature 311, 65–67 (1984).
Wagner, E. F., Covarrubias, L., Stewart, T. A. & Mintz, B. Cell 35, 647–655 (1983).
Durnam, D. M. & Palmiter, R. D. J. biol. Chem. 256, 5712–5716 (1981).
Mayo, K. E., Warren, R. & Palmiter, R. D. Cell 29, 99–108 (1982).
Brinster, R. L., Chen, H. Y., Warren, R., Sarthy, A. & Palmiter, R. D. Nature 296, 39–42 (1982).
Palmiter, R. D., Chen, H. Y. & Brinster, R. L. Cell 29, 701–710 (1982).
Graham, F. L. & Van der Eb, A. J. Virology 52, 456–467 (1973).
Southern, P. J. & Berg, P. J. molec. appl. Genet. 1, 327–341 (1982).
Brinster, R. L. et al. Cell 27, 223–231 (1981).
Wehrenberg, W. B., Bloch, B. & Phillips, B. J. Endocrinology 115, 1218–1220 (1984).
Frohman, L. A. & Szabo, M. in Physiopathology of Endocrine Diseases and Mechanisms of Hormone Action, 259–271 (Liss, New York, 1981).
Thorner, M. O. et al. J. clin. Invest. 70, 965–977 (1982).
Asa, S. L. et al. J. clin. Endocr. Metab. 58, 796–803 (1984).
Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J. & Rutter, W. J. Biochemistry 18, 5294–5299 (1979).
Meinkoth, J. & Wahl, G. M. Analyt. Biochem. 138, 267–284 (1984).
Thomas, P. Proc. natn. Acad. Sci. U.S.A. 77, 5201–5205 (1980).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hammer, R., Brinster, R., Rosenfeld, M. et al. Expression of human growth hormone-releasing factor in transgenic mice results in increased somatic growth. Nature 315, 413–416 (1985). https://doi.org/10.1038/315413a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/315413a0
This article is cited by
-
The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes
Reviews in Endocrine and Metabolic Disorders (2020)
-
Identification and characterization of new functional truncated variants of somatostatin receptor subtype 5 in rodents
Cellular and Molecular Life Sciences (2010)
-
p27Kip1-deficient mice exhibit accelerated growth hormone-releasing hormone (GHRH)-induced somatotrope proliferation and adenoma formation
Oncogene (2000)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.